Giuseppe Perrone

Scopus Publications

Adequacy criteria and reporting for prognostic and predictive profiling of biopsies from gastrointestinal neoplasia: A position paper from the Italian group of gastrointestinal pathologists, section of Italian society of anatomic pathology and cytology (GIPAD-SIAPeC-IAP)
Paola Parente, Federica Grillo, Matilde Callegarin, Claudio Luchini, Massimo Milione, Paola Mattiolo, Roberta Gafà, Fabio Pagni, Umberto Malapelle, Maria Cristina Macciomei, Carla Giordano, Maria D’Armiento, Maria Raffaella Ambrosio, Francesco Vasuri, Daniela Fanni, Giuseppe Ingravallo, Francesco Giuseppe Carbone, Emanuela Pilozzi, Enrico Falco, Giuseppe Perrone, Alessandro Caputo, Iacopo Panarese, Giancarlo Pruneri, Paola Cassoni, Alessandro Gambella, Luca Savino, Valentina Angerilli, Alessandro Vanoli, Luca Mastracci, Matteo Fassan
Digestive and Liver Disease, 2026
Osimertinib-Induced Lung Injury and Treatment Rechallenge: Clinical Insights From a Case Report With a Comprehensive Literature Review
Fabrizio Citarella, Emanuele C. Mingo, Matteo Fiorenti, Marco Russano, Giuseppe Perrone, Giulia La Cava, Valentina Santo, Alessia Vendittelli, Leonardo Brunetti, Cecilia Saracino, Ludovica Esposito, Andrea Malgeri, Sara Ramella, Bruno Vincenzi, Giuseppe Tonini, Alessio Cortellini
Clinical Lung Cancer, 2026
Osimertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) widely used in EGFR mutant non-small cell lung cancer (NSCLC). Despite a favorable safety profile, osimertinib-induced lung injury (OILI) remains a rare but clinically significant adverse event. Guidelines recommend permanent discontinuation after severe cases; the rechallenge feasibility in selected patients remains an area of ongoing debate. We report a case of a 70-year-old patient with EGFR mutant NSCLC who developed grade 4 OILI requiring hospitalization. After resolution with corticosteroids, treatment was switched to afatinib. The patient later progressed showing a de novo EGFR T790M mutation and MET amplification. Considering the limited treatment options, a carefully monitored osimertinib rechallenge at a reduced dose (40 mg/d) was attempted. The patient tolerated treatment without pneumonitis recurrence and achieved disease control for several months before ultimately progressing. To contextualize this case, we conducted a scoping review of the available literature on osimertinib administration after lung toxicity. Among 27 studies comprising 1645 patients, 449 (27.3%) developed OILI. One hundred eighty nine (42%) were re-treated, either with (114) or without (75) a temporary interruption. The reported risk of recurrence after rechallenge was low, particularly in cases of mild-to-moderate lung injury. In more severe cases the risk was difficult to determine based on the clinical details available. This study highlights the heterogeneous approaches to OILI and the potential feasibility of rechallenge in selected patients. Given the expanding osimertinib use for early and advanced stage NSCLC, further research is warranted to refine treatment decisions and optimize patient safety.
Integrated mutational landscape analysis of endometrial stromal sarcoma
Tobias M. P. Hartwich, Seungji Choi, Ayoung Hwang, Stefania Bellone, Luca Palmieri, Hae Seo, Taekeun Kim, Juhyeon Hong, Camilla Krakstad, Jone Trovik, Ingunn M. Stefansson, Hans Kristian Haugland, Michelle Greenman, Victoria Ettorre, Sarah Ottum, Cem Demirkiran, Yang Yang-Hartwich, Natalia Buza, Pei Hui, Salvatore Lopez, Gennaro Cormio, Mariantonietta Ramunno, Alfredo Zito, Emanuele Perrone, Anna Fagotti, Francesco Fanfani, Angela Santoro, Antonella Ravaggi, Eliana Bignotti, Franco Odicino, Laura Ardighieri, Elena Ratner, Roberto Angioli, Giuseppe Perrone, Daniela Luvero, Beatrice Conca, Jungmin Choi, Joseph Schlessinger, Alessandro D. Santin
Proceedings of the National Academy of Sciences of the United States of America, 2026
Endometrial stromal sarcoma (ESS) is a rare uterine malignancy with limited treatment options. We performed integrated whole-genome, whole-exome, and transcriptome sequencing on 80 ESS tumors, comprising 32 low-grade (LG) and 48 high-grade (HG) tumors, to characterize their genetic landscape. The overall mutation burden was modest, with no significant difference between grades; however, we identified six hypermutated cases (7.5%) harboring POLE or mismatch repair mutations, genomic features predictive of immunotherapy response. We identified focal RAD54B amplifications in 15 tumors (18.8%), leading to elevated RAD54B expression and significantly shorter survival. This establishes RAD54B as an oncogenic driver in ESS. Known tumor suppressors (PTEN, TP53) were frequently mutated in HG-ESS but rare in LG-ESS, highlighting distinct grade-specific drivers of malignancy. HG-ESS exhibited widespread chromosomal gains, frequent loss of cell-cycle regulators (RB1, CDKN2A), and numerous private gene fusions arising from complex DNA rearrangements. In contrast, LG-ESS were defined by canonical fusions (e.g., JAZF1–SUZ12 ) and co-occurring deletions in metabolic regulator genes (TSC2, STK11). Finally, in an activating NRAS-mutant (p.Q61R) HG-ESS xenograft, the combination of MEK and FAK inhibition dramatically suppressed tumor growth and prolonged survival, highlighting a promising targeted treatment strategy. Overall, our comprehensive analysis defines the molecular basis of ESS and provides a strong preclinical rationale for precision therapies in this aggressive cancer.
Molecular Landscape of Resected Thymomas: Insights from Mutational Profiling
Luca Frasca, Antonio Sarubbi, Lorenzo Nibid, Ilaria Suriano, Filippo Longo, Giovanna Sabarese, Daniela Righi, Giuseppe Perrone, Pierfilippo Crucitti
Diagnostics, 2026
Background/Objectives: Thymomas are the most common tumors of the anterior mediastinum. While early-stage disease often has a favorable prognosis, therapeutic options in advanced stages remain limited. Moreover, the molecular profile of thymomas is still poorly characterized. In the present study, we explored the presence of targetable mutations and programmed death-ligand 1 (PD-L1) expression in a cohort of surgically resected thymomas. Furthermore, we investigated the correlation between PD-L1 expression, histological subtype, and risk of recurrence in patients who underwent curative-intent thymectomy. Methods: Mutational profiling was performed using a DNA-based NGS Cancer Panel of 16 genes. PD-L1 expression was evaluated via Tumor Proportion Score (TPS), and thymomas with TPS ≥ 50% were identified as high expressors. The associations with histological subtype and disease-free survival (DFS) were analyzed using logistic regression, Cox proportional hazards models, and Kaplan–Meier survival curves. Results: In our study, 2/37 (5.4%) of tested neoplasms (type AB and B2 thymoma) reported as a PIK3CA mutation; no other targetable mutations were observed. Moreover, high PD-L1 expression (≥50%) was reported in (15/37) 40.5% of patients and was significantly associated with aggressive histological subtypes (B2 and B3) (p < 0.001). Logistic regression analysis showed that high PD-L1 expression was a significant predictor of aggressive histology (McFadden’s R2 = 0.268, p < 0.001), with an odds ratio of 15.5 (95% CI: 2.9–83.4; p = 0.001). During follow-up, 5/37 (13.5%) of patients experienced disease recurrence; however, no significant difference in DFS was found between high and low PD-L1 expression groups. Conclusions: Our data confirm the presence of PIK3CA mutations in thymomas and encourage the exploration the potential role of molecular target therapy in this setting. Moreover, we underlined that high PD-L1 expression level is associated with more aggressive thymoma subtypes and may have a role as a prognostic biomarker. These findings support the need for further studies on the potential role of molecular and predictive pathology in thymic epithelial tumors.
HugoTM RAS vs Da Vinci® Xi Robot-Assisted Partial Nephrectomy: First Propensity Score-Matched Comparison of Perioperative and Functional Outcomes
Francesco Prata, Riccardo Mastroianni, Giuseppe Simone, Francesco Tedesco, Umberto Anceschi, Alberto Ragusa, Angelo Civitella, Aldo Brassetti, Alfredo Maria Bove, Andrea Iannuzzi, Alfredo Travino, Alessandro De Giuseppe, Marco Fantozzi, Mariavittoria Vescovo, Simone D’Annunzio, Mariaconsiglia Ferriero, Rocco Simone Flammia, Salvatore Guaglianone, Leonardo Misuraca, Flavia Proietti, Gabriele Tuderti, Costantino Leonardo, Giuseppe Perrone, Roberto Mario Scarpa, Rocco Papalia
Journal of Endourology, 2026
Purpose: To report the first multicentric comparison between Hugo™ robot-assisted surgery/system (RAS) and Da Vinci® Xi for robot-assisted partial nephrectomy (RAPN). Methods: Between October 2022 and March 2024, a total of 258 patients underwent off-clamp RAPN (Hugo RAS = 52 patients, and Da Vinci = 206 patients). Da Vinci and Hugo cases were matched in a 1:1 ratio using propensity score matching (PSM), adjusting for the Radius Exophytic Nearness Anterior Location score and renorrhaphy technique. Trifecta was defined as the coexistence of negative surgical margin status, no Clavien–Dindo grade ≥ 3 complications, and ≤ 30% estimated glomerular filtration rate (eGFR) reduction at discharge. Results: After 1:1 PSM, two comparable populations of 52 patients each were selected. No intraoperative blood transfusion occurred in any group. The Hugo cohort displayed a higher rate of postoperative transfusions (7.7% vs 0%, p = 0.04). Nevertheless, perioperative complications were comparable ( p = 0.32). The median length of stay (LOS) was shorter in the Da Vinci group (2 days vs 3 days, p < 0.001), as for median eGFR at discharge (74.5 mL/min/1.73m 2 vs 87.3 mL/min/1.73m 2 , p = 0.03). No significant difference in positive surgical margins was shown between the two groups ( p = 0.08). Finally, a comparable Trifecta rate was achieved for both platforms (88.5% in the Hugo RAS group and 90.4% in the Da Vinci group, p = 0.75). Conclusions: Despite the hierarchical role of Da Vinci in the robotic surgical landscape, RAPN can be safely carried out with the new Hugo RAS System, with satisfactory perioperative surgical outcomes comparable to the Da Vinci Xi System.
A Nanostring gene expression approach identifies aggressive clinical behavior related genes in dedifferentiated liposarcoma
Francesca Zalfa, Paolo Manca, Simone Carotti, Silvia Vallese, Daniela Righi, Chiara Taffon, Lorenzo Nibid, Marta Sbaraglia, Carla Rabitti, Francesco Pantano, Giuseppe Tonini, Angelo Paolo Dei Tos, Bruno Vincenzi, Giuseppe Perrone
Scientific Reports, 2025
Dedifferentiated liposarcoma (DDLPS) is one of the most common subtypes of soft tissue sarcoma with a highly variable clinical behavior. Despite advanced molecular approaches are exploring the genetic panorama of DDLPS progression, to date the driver genes of the aggressive clinical behavior in DDLPS have not been identified yet. Here, we used a Nanostring nCounter approach to study the gene expression profile of 60 selected genes involved in DDLPS progression, in a cohort of DDLPS with aggressive clinical behavior, in comparison to a cohort of DDLPS with indolent clinical behavior. We identified five genes whose expression is significantly and consistently altered in aggressive compared to indolent DDLPS. Moreover, by a clinical outcome analyses we found MAP3K12 gene expression linked with both a higher risk of metastases and death. We envisage that the identified genes could represent the first genes of a genetic signature able to predict the clinical evolution of a DDLPS.
ESR1 testing on FFPE samples from metastatic lesions in HR + /HER2- breast cancer after progression on CDK4/6 inhibitor therapy
Konstantinos Venetis, Giulia Cursano, Roberta Scafetta, Pier Paolo Maria Berton Giachetti, Alberto Concardi, Elisa De Camilli, Marianna D’Ercole, Eltjona Mane, Chiara Frascarelli, Antonio Marra, Sara Gandini, Francesco Pepe, Simone Scagnoli, Silvia Maria Rossi, Raffaella Troiano, Elena Speziale, Carmine De Angelis, Giancarlo Troncone, Umberto Malapelle, Giuseppe Perrone, Andrea Botticelli, Giuseppe Viale, Giuseppe Curigliano, Elena Guerini Rocco, Carmen Criscitiello, Nicola Fusco
Breast Cancer Research, 2025
Mutations in ESR1 play a critical role in resistance to endocrine therapy (ET) in hormone receptor-positive (HR +)/HER2- metastatic breast cancer (MBC). Testing for ESR1 mutations is essential for guiding treatment with novel oral selective estrogen receptor degraders (SERDs) like elacestrant or camizestrant. While most studies have utilized liquid biopsy (LB) for mutation detection, the role of formalin-fixed paraffin-embedded (FFPE) tissue biopsy in this context remains unclear. In this study, we analyzed a cohort of HR + /HER2- MBC patients who experienced resistance to ET and CDK4/6 inhibitors. Next-generation sequencing (NGS) was performed on FFPE biopsy samples obtained from metastatic sites at the time of disease progression. ESR1 mutations were detected in 24 out of 38 patients (63.2%), with p.D538G identified in 10 patients (45.5%) and p.Y537S in 6 patients (27.2%) as the most frequent alterations. One patient exhibited dual ESR1 mutations, and a recurrent ESR1-CCDC170 gene fusion was identified, underscoring the diversity and potential interplay of genetic alterations driving resistance in HR + /HER2- MBC. Notably, lung metastases were significantly more common in ESR1 mutant cases (8/24, 33.3%) compared to wild-type cases (1/14, 7.1%), while liver metastases showed no difference between mutant (12/24, 50.0%) and wild-type groups (7/14, 50.0%). Co-mutations in actionable pathways, particularly PIK3CA, were observed in n = 10 ESR1 mutant tumors (41.6%), highlighting their contribution to resistance mechanisms and posing significant challenges for treatment selection, as these alterations may necessitate combination therapies to effectively target multiple resistance pathways. This study presents new insights into the prevalence and clinical significance of ESR1 mutations in HR + /HER2- MBC, highlighting the potential utility of FFPE biopsy samples as a viable alternative or complementary approach to LB for mutation detection, particularly in resource-limited settings where access to ctDNA analysis may be constrained.
The Italian Portrait of Laboratory Information Systems in Pathology: The Ones We Have and the Ones We Would Like
Stefano Marletta, Marco Maria Baron, Vincenzo L’Imperio, Aldo Scarpa, Alessandro Caputo, Giuseppe Perrone, Francesco Merolla, Umberto Malapelle, Matteo Fassan, Angelo Paolo Dei Tos, Fabio Pagni, Albino Eccher
Journal of Personalized Medicine, 2025
Background: In the evolving landscape of pathology, Laboratory Information Systems (LISs) have become essential tools for ensuring traceability, efficiency, and data security in diagnostic workflows. Methods: This study presents a comprehensive comparative analysis of three major LIS platforms used in Italian pathology laboratories in 2025: Armonia (Dedalus), Pathox Web (Tesi Group), and WinSAP 3.0 (Engineering). Each system is evaluated across key parameters, including sample traceability, integration with hospital systems, digital reporting, user interface, and compliance with regulatory standards such as GDPR and ISO 15189. Results: Armonia stands out for its advanced integration capabilities, scalability, and support for digital pathology, making it ideal for large institutions. Pathox Web offers a balanced solution with strong usability and web-based accessibility, suitable for medium-sized laboratories. WinSAP 3.0, while more limited in modern features, remains a stable and cost-effective option for many facilities. This study emphasizes the strategic importance of selecting an LIS aligned with institutional needs, highlighting its role in enhancing diagnostic quality, operational safety, and future integration with artificial intelligence and automation. Conclusions: The findings support informed decision-making in LIS adoption, critically contributing to the management of scientific and economic data of pathology services in Italy.
Oncotype DX in clinical practice: Impact on treatment decisions and healthcare system economy
Alessia Capozzi, Silvia Maria Rossi, Giovanna Sabarese, Marco Germani, Gabriella Gullotta, Stefania Sfregola, Giuseppe Perrone
Pathologica, 2025
Objective: The aim of this study is to assess the impact of Oncotype DX on treatment decisions and healthcare economy. Methods: Data were retrospectively collected from Fondazione Policlinico Universitario Campus Bio-Medico of Rome. 313 female patients with HR-positive, HER2-negative breast cancer underwent Oncotype DX between August 2020 and January 2024. Recurrence score, recurrence risk and chemotherapy benefit were collected from Oncotype DX report. Clinical and pathological data were collected. To objectify the oncological prescription based on clinicopathological variables, we used PREDICT 2.2 algorithm. Reimbursements, hospital accesses and number of health services in one-year follow-up were also collected. Results: Oncotype DX did not indicate chemotherapy in 223/313 (71.2%) patients. In the PREDICT 2.2 scenario, 147/313 (47%) patients were not indicated chemotherapy. Thus, genomic test approach led to a decrease of 24.2% in chemotherapy prescription. Patients receiving chemotherapy had 21 (+91.3%) more hospital accesses, 115 (+101.8%) more health services and a reimbursement of €2811 (+31.5%) higher than patients not receiving chemotherapy (median values). Conclusions: Oncotype DX results in lower rates of chemotherapy prescription and in possible healthcare cost savings.
Doctor-in-the-Loop: An explainable, multi-view deep learning framework for predicting pathological response in non-small cell lung cancer
Alice Natalina Caragliano, Filippo Ruffini, Carlo Greco, Edy Ippolito, Michele Fiore, Claudia Tacconi, Lorenzo Nibid, Giuseppe Perrone, Sara Ramella, Paolo Soda, Valerio Guarrasi
Image and Vision Computing, 2025
Non-small cell lung cancer (NSCLC) remains a major global health challenge, with high post-surgical recurrence rates underscoring the need for accurate pathological response predictions to guide personalized treatments. Although artificial intelligence models show promise in this domain, their clinical adoption is limited by the lack of medically grounded guidance during training, often resulting in non-explainable intrinsic predictions. To address this, we propose Doctor-in-the-Loop , a novel framework that integrates expert-driven domain knowledge with explainable artificial intelligence techniques, directing the model toward clinically relevant anatomical regions and improving both interpretability and trustworthiness. Our approach employs a gradual multi-view strategy, progressively refining the model’s focus from broad contextual features to finer, lesion-specific details. By incorporating domain insights at every stage, we enhance predictive accuracy while ensuring that the model’s decision-making process aligns more closely with clinical reasoning. Evaluated on a dataset of NSCLC patients, Doctor-in-the-Loop delivers promising predictive performance and provides transparent, justifiable outputs, representing a significant step toward clinically explainable artificial intelligence in oncology.
Harmonization trial on ESR1 testing strategies in ER+/HER2- breast cancer patients: an Italian experience
Francesco Pepe, Gianluca Russo, Konstantinos Venetis, Claudia Scimone, Lucia Palumbo, Mariantonia Nacchio, Domenica di Giovanni, Claudia Sarracino, Ilaria Tomaiuolo, Elisabetta Zulato, Matteo Fassan, Daniela Righi, Giuseppe Perrone, Dario de Biase, Gabriele Casati, Fabio Pagni, Lucia Gullotti, Antonio Rizzo, Alessandro Perez, Antonio Russo, Katia Zavaglia, Gianluca Gragnano, Domenico Cozzolino, Sabrina Alfano, Cristian Scatena, Sara D’andrea, Monica Schiappacassi, Giuseppina Roscigno, Alessia Paganotti, Renzo Boldorini, Francesco Esposito, Pierlorenzo Pallante, Daniela Furlan, Marta Sbaraglia, Angelo Paolo Dei Tos, Giancarlo Troncone, Nicola Fusco, Umberto Malapelle
Journal of Liquid Biopsy, 2025
Co-Occurrence of Anti-Synthetase Syndrome and Sjögren Disease: A Case-Based Review
Andrea Pilato, Giorgio D’Avanzo, Francesca Di Nunzio, Annalisa Marino, Alessia Gallo, Irene Genovali, Letizia Pia Di Corcia, Chiara Taffon, Giuseppe Perrone, Vasiliki Liakouli, Luca Navarini, Roberto Giacomelli, Onorina Berardicurti, Raffaele Antonelli Incalzi
Journal of Clinical Medicine, 2025
Clinical implications of epithelial-to-mesenchymal transition in cancers which potentially spread to peritoneum
Ludovico Carbone, Giosuè Giordano Incognito, Dalila Incognito, Lorenzo Nibid, Giuseppe Caruso, Massimiliano Berretta, Chiara Taffon, Marco Palumbo, Giuseppe Perrone, Franco Roviello, Daniele Marrelli
Clinical and Translational Oncology, 2025
The routine use of a digital tool for the tumor cell fraction quantification in molecular pathology: an international validation of QuANTUM
Vincenzo L’Imperio, , Giulia Capitoli, Giorgio Cazzaniga, Mauro Mannino, Francesca Bono, Davide Seminati, Catarina Eloy, Joao Pinto, Elena Guerini Rocco, Matteo Fassan, Pasquale Pisapia, Francesco Pepe, Lara Pijuan, Jordi Temprana-Salvador, Antonio Polonia, Syed Ali Khurram, Emanuela Bonoldi, Alessandro Marando, Giuseppe Perrone, Stefania Galimberti, Giancarlo Troncone, Umberto Malapelle, Fabio Pagni
Pathologica, 2025
Clinical, Morphologic, and Genomic Findings in Spitz Tumors With RET Fusion: A Series of 31 Cases
Michele Donati, Dimitrios Goutas, Daniel Pissaloux, Shantel Olivares, Thibault Kervarrec, Daniel Nosek, Keisuke Goto, Julie Lemahieu, Siebe Loontiens, Joni Van der Meulen, Boulos Mansour, Giuseppe Perrone, Nicolas Macagno, Pedram Gerami, Dmitry V. Kazakov, Arnaud De la Fouchardiere
Modern Pathology, 2025
Storage Time and DNA Quality Determine BRCA1/2 Sequencing Success in Prostate Cancer: A Multicentre Analysis with Therapeutic Implications
Mariavittoria Vescovo, Maria Rosaria Raspollini, Lorenzo Nibid, Francesca Castiglione, Eleonora Nardi, Dario de Biase, Francesco Massari, Francesca Giunchi, Francesco Pepe, Giancarlo Troncone, Umberto Malapelle, Mariantonia Carosi, Beatrice Casini, Elisa Melucci, Matteo Fassan, Luisa Toffolatti, Elena Guerini-Rocco, Federica Conversano, Alessandra Rappa, Stefania Tommasi, Claudio Antonio Coppola, Pio Zeppa, Alessandro Caputo, Sara Gaeta, Fabio Pagni, Davide Seminati, Andrea Vecchione, Stefania Scarpino, Daniela Righi, Chiara Taffon, Francesco Prata, Giuseppe Perrone
Cancers, 2025
Biopsy in chronic liver disease: proposal for a shared path between clinicians and pathologists
Andrea Baiocchini, Maria Conti, Daniela Fanni, Francesca Romana Ponziani, Giuliano Alagna, Clara Balsano, Simone Carotti, Antonio Cossu, Guido Delle Monache, Shirin Demma, Maria Cristina Giustiniani, Vito Gomes, Cristina Manieli, Alessandra Moretti, Teresa Musarra, Valeria Pace Palitti, Giuseppe Perrone, Chiara Taffon, Francesca Terracciani, Umberto Vespasiani-Gentilucci, Teresa Zolfino, Giulia d’Amati
Pathologica, 2025
Burden of Disease of Breast Cancer in Italy: A Real-World Data Analysis
F. S. Mennini, A. Marcellusi, P. Sciattella, M. Scortichini, Angela Ragonese, F. Cattel, R. D’Antona, L. Del Mastro, S. Gori, G. Perrone, R. Migliorini, M. Trabucco Aurilio
Pharmacoeconomics Open, 2025
Deep Learning Model for Predicting Immunotherapy Response in Advanced Non-Small Cell Lung Cancer
Mehrdad Rakaee, Masoud Tafavvoghi, Biagio Ricciuti, Joao V. Alessi, Alessio Cortellini, Fabrizio Citarella, Lorenzo Nibid, Giuseppe Perrone, Elio Adib, Claudia A. M. Fulgenzi, Cassio Murilo Hidalgo Filho, Alessandro Di Federico, Falah Jabar, Sayed Hashemi, Ilias Houda, Elin Richardsen, Lill-Tove Rasmussen Busund, Tom Donnem, Idris Bahce, David J. Pinato, Åslaug Helland, Lynette M. Sholl, Mark M. Awad, David J. Kwiatkowski
JAMA Oncology, 2025
Multimodal Doctor-in-the-Loop: A Clinically-Guided Explainable Framework for Predicting Pathological Response in Non-Small Cell Lung Cancer
Alice Natalina Caragliano, Claudia Tacconi, Carlo Greco, Lorenzo Nibid, Edy Ippolito, Michele Fiore, Giuseppe Perrone, Sara Ramella, Paolo Soda, Valerio Guarrasi
Proceedings of the International Joint Conference on Neural Networks, 2025
Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+/HER2− metastatic breast cancer
Umberto Malapelle, Simonetta Buglioni, Isabella Castellano, Carmen Criscitiello, Giuseppe Curigliano, Giulia d’Amati, Carmine De Angelis, Dario de Biase, Francesco Pepe, Giuseppe Perrone, Cristian Scatena, Maria Scatolini, Dario Trapani, Konstantinos Venetis, Nicola Fusco
Pathologica, 2025
S-p-bromobenzyl-glutathione cyclopentyl diester (BBGC) as novel therapeutic strategy to enhance trabectedin anti-tumor effect in soft tissue sarcoma preclinical models
F. Pantano, S. Simonetti, M. Iuliani, M. J. Guillen, C. Cuevas, P. Aviles, S. Cavaliere, A. Napolitano, A. Cortellini, A. Mazzocca, L. Nibid, G. Sabarese, G. Perrone, M. Gambarotti, A. Righi, E. Palmerini, S. Stacchiotti, M. Barisella, A. Gronchi, S. Valeri, M. Sbaraglia, A. P. Dei Tos, G. Tonini, B. Vincenzi
Oncogene, 2024
RNA-Seq Analysis in Non-Small Cell Lung Cancer: What Is the Best Sample from Clinical Practice?
Lorenzo Nibid, Giovanna Sabarese, Luca Andreotti, Benedetta Canalis, Daniela Righi, Filippo Longo, Margherita Grazi, Pierfilippo Crucitti, Giuseppe Perrone
Journal of Personalized Medicine, 2024
Colonic Epithelial Permeability to Ions Is Restored after Vedolizumab Treatment and May Predict Clinical Response in Inflammatory Bowel Disease Patients
Michele Cicala, Manuele Gori, Paola Balestrieri, Annamaria Altomare, Alessandro Tullio, Simone Di Cola, Sander Dejongh, Maria Giovanna Graziani, Cristiano Pagnini, Simone Carotti, Giuseppe Perrone, Mentore Ribolsi, Marcello Fiorani, Michele P. L. Guarino, Ricard Farré
International Journal of Molecular Sciences, 2024
Exploring the Role of the MUTYH Gene in Breast, Ovarian and Endometrial Cancer
Carla Lintas, Benedetta Canalis, Alessia Azzarà, Giovanna Sabarese, Giuseppe Perrone, Fiorella Gurrieri
Genes, 2024
Non-Small Cell Lung Cancer Testing on Reference Specimens: An Italian Multicenter Experience
Francesco Pepe, Gianluca Russo, Alessandro Venuta, Claudia Scimone, Mariantonia Nacchio, Pasquale Pisapia, Gaia Goteri, Francesca Barbisan, Caterina Chiappetta, Angelina Pernazza, Domenico Campagna, Marco Giordano, Giuseppe Perrone, Giovanna Sabarese, Annalisa Altimari, Dario de Biase, Giovanni Tallini, Daniele Calistri, Elisa Chiadini, Laura Capelli, Alfredo Santinelli, Anna Elisa Gulini, Elisa Pierpaoli, Manuela Badiali, Stefania Murru, Riccardo Murgia, Elena Guerini Rocco, Konstantinos Venetis, Nicola Fusco, Denise Morotti, Andrea Gianatti, Daniela Furlan, Giulio Rossi, Laura Melocchi, Maria Russo, Caterina De Luca, Lucia Palumbo, Saverio Simonelli, Antonella Maffè, Paola Francia di Celle, Tiziana Venesio, Maria Scatolini, Enrico Grosso, Sara Orecchia, Matteo Fassan, Mariangela Balistreri, Elisabetta Zulato, Daniela Reghellin, Elena Lazzari, Maria Santacatterina, Maria Liliana Piredda, Manuela Riccardi, Licia Laurino, Elena Roz, Domenico Longo, Daniela Petronilla Romeo, Carmine Fazzari, Andrea Moreno-Manuel, Giuseppe Diego Puglia, Andrey D. Prjibelski, Daria Shafranskaya, Luisella Righi, Angela Listì, Domenico Vitale, Antonino Iaccarino, Umberto Malapelle, Giancarlo Troncone
Oncology and Therapy, 2024
PD-L1 testing in metastatic triple negative breast cancer: Results of an Italian survey
Bruna Cerbelli, Alessio Cirillo, Giulia Pomati, Angelina Pernazza, Andrea Ascione, Simona Pisegna, Annalinda Pisano, Martina Leopizzi, Maria Gemma Pignataro, Leopoldo Costarelli, Antonino Mulè, Andrea Vecchione, Piera Catalano, Luigi Coppola, Giuseppe Perrone, Letizia Perracchio, Lucia Anemona, Antonio Mastracchio, Stefano Nardi, Renato Reitano, Annalisa Massari, Lucia Rosalba Grillo, Fabrizio Liberati, Carlo Della Rocca, Paolo Marchetti, Andrea Botticelli, Giulia D’Amati
Tumori, 2024
Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: Practical indications from an Italian multidisciplinary group
Umberto Malapelle, Alessandro Delle Donne, Fabio Pagni, Filippo Fraggetta, Elena Guerini Rocco, Giulia Pasello, Giuseppe Perrone, Francesco Pepe, Simona Vatrano, Sandro Pignata, Carmine Pinto, Giancarlo Pruneri, Antonio Russo, Hector J. Soto Parra, Stefania Vallone, Antonio Marchetti, Giancarlo Troncone, Silvia Novello
Critical Reviews in Oncology Hematology, 2024
The central role of pathology labs in breast cancer precision oncology: a call for action
Giancarlo Pruneri, Daniele Lorenzini, Mauro G. Mastropasqua, Giuseppe Perrone, Antonio Rizzo, Donatella Santini, Chiara C. Volpi, Saverio Cinieri, Alberto Zambelli, Anna Sapino, Isabella Castellano
Npj Breast Cancer, 2023
Think “HER2” different: integrative diagnostic approaches for HER2-low breast cancer
Caterina Marchiò, Carmen Criscitiello, Cristian Scatena, Alfredo Santinelli, Paolo Graziano, Umberto Malapelle, Giulia Cursano, Konstantinos Venetis, Giuseppe Nicolò Fanelli, Francesco Pepe, Enrico Berrino, Carmine De Angelis, Giuseppe Perrone, Giuseppe Curigliano, Nicola Fusco
Pathologica, 2023
Network approach in liquidomics landscape
Daniele Santini, Andrea Botticelli, Antonio Galvano, Michele Iuliani, Lorena Incorvaia, Valerio Gristina, Chiara Taffon, Simone Foderaro, Elisa Paccagnella, Sonia Simonetti, Federico Fazio, Simone Scagnoli, Giulia Pomati, Francesco Pantano, Giuseppe Perrone, Elena De Falco, Antonio Russo, Gian Paolo Spinelli
Journal of Experimental and Clinical Cancer Research, 2023
Author Correction: Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer (npj Breast Cancer, (2021), 7, 1, (1), 10.1038/s41523-020-00208-2)
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Npj Breast Cancer, 2023
Deep pathomics: A new image-based tool for predicting response to treatment in stage III non-small cell lung cancer
Lorenzo Nibid, Carlo Greco, Ermanno Cordelli, Giovanna Sabarese, Michele Fiore, Charles Z. Liu, Edy Ippolito, Rosa Sicilia, Marianna Miele, Matteo Tortora, Chiara Taffon, Mehrdad Rakaee, Paolo Soda, Sara Ramella, Giuseppe Perrone
Plos One, 2023
Histologic and Immunohistochemical Evaluation of Human Breast Capsules Formed around Five Different Expander Surfaces
Barbara Cagli, Simone Carotti, Francesco Segreto, Maria Francesconi, Giovanni F. Marangi, Stefania Tenna, Michele Diomedi, Giuseppe Perrone, Sergio Morini, Paolo Persichetti
Plastic and Reconstructive Surgery, 2023
Type 2 Diabetes Mellitus and Efficacy Outcomes from Immune Checkpoint Blockade in Patients with Cancer
Alessio Cortellini, Antonio D'Alessio, Siobhan Cleary, Sebastiano Buti, Melissa Bersanelli, Paola Bordi, Giuseppe Tonini, Bruno Vincenzi, Marco Tucci, Alessandro Russo, Francesco Pantano, Marco Russano, Luigia Stefania Stucci, Maria Chiara Sergi, Martina Falconi, Maria Antonietta Zarzana, Daniele Santini, Francesco Spagnolo, Enrica T. Tanda, Francesca Rastelli, Francesca Chiara Giorgi, Federica Pergolesi, Raffaele Giusti, Marco Filetti, Francesca Lo Bianco, Paolo Marchetti, Andrea Botticelli, Alain Gelibter, Marco Siringo, Marco Ferrari, Riccardo Marconcini, Maria Giuseppa Vitale, Linda Nicolardi, Rita Chiari, Michele Ghidini, Olga Nigro, Francesco Grossi, Michele De Tursi, Pietro Di Marino, Paola Queirolo, Sergio Bracarda, Serena Macrini, Alessandro Inno, Federica Zoratto, Enzo Veltri, Chiara Spoto, Maria Grazia Vitale, Katia Cannita, Alessandra Gennari, Daniel L. Morganstein, Domenico Mallardo, Lorenzo Nibid, Giovanna Sabarese, Leonardo Brunetti, Giuseppe Perrone, Paolo A. Ascierto, Corrado Ficorella, David J. Pinato
Clinical Cancer Research, 2023
The ideal reporting of RAS testing in colorectal adenocarcinoma: a pathologists’ perspective
Umberto Malapelle, Valentina Angerilli, Francesco Pepe, Gabriella Fontanini, Sara Lonardi, Mario Scartozzi, Lorenzo Memeo, Gianfranco Pruneri, Antonio Marchetti, Giuseppe Perrone, Matteo Fassan
Pathologica, 2023
Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis
Federica Tavaglione, Oveis Jamialahmadi, Antonio De Vincentis, Sami Qadri, Mohammad Erfan Mowlaei, Rosellina Margherita Mancina, Ester Ciociola, Simone Carotti, Giuseppe Perrone, Vincenzo Bruni, Ida Francesca Gallo, Dario Tuccinardi, Cristiana Bianco, Daniele Prati, Silvia Manfrini, Paolo Pozzilli, Antonio Picardi, Marco Caricato, Hannele Yki-Järvinen, Luca Valenti, Umberto Vespasiani-Gentilucci, Stefano Romeo
Clinical Gastroenterology and Hepatology, 2023
FGFR2 testing in cholangiocarcinoma: translating molecular studies into clinical practice
Valentina Angerilli, Lorenzo Fornaro, Francesco Pepe, Silvia Maria Rossi, Giuseppe Perrone, Umberto Malapelle, Matteo Fassan
Pathologica, 2023
Feasibility of Comprehensive Genomic Profiling (CGP) in Real-Life Clinical Practice
Lorenzo Nibid, Giovanna Sabarese, Daniela Righi, Silvia Maria Rossi, Giorgia Merlini, Pierfilippo Crucitti, Bruno Vincenzi, Giuseppe Tonini, Giuseppe Perrone
Diagnostics, 2023
Long-Term Sequential Digital Dermoscopy of Low-Risk Patients May Not Improve Early Diagnosis of Melanoma Compared to Periodical Handheld Dermoscopy
Riccardo Borroni, Vincenzo Panasiti, Mario Valenti, Luigi Gargiulo, Giuseppe Perrone, Roberta Dall’Alba, Clarissa Fava, Francesco Sacrini, Luca Mancini, Sofia Manara, Emanuela Morenghi, Antonio Costanzo
Cancers, 2023
RadioPathomics: Multimodal Learning in Non-Small Cell Lung Cancer for Adaptive Radiotherapy
Matteo Tortora, Ermanno Cordelli, Rosa Sicilia, Lorenzo Nibid, Edy Ippolito, Giuseppe Perrone, Sara Ramella, Paolo Soda
IEEE Access, 2023
Subaxillary Replacement Flap Compared with the Round Block Displacement Technique in Oncoplastic Breast Conserving Surgery: Functional Outcomes of a Feasible One Stage Reconstruction
Paolo Orsaria, Antonella Grasso, Georgeta Soponaru, Francesca Carnevale, Virginia Scorsone, Edy Ippolito, Francesco Pantano, Matteo Sammarra, Claudia Piccolo, Michele Altomare, Giuseppe Perrone, Vittorio Altomare
Current Oncology, 2022
DOG-1 positive primary acinic cell carcinoma of the lung and investigation of molecular status
Lorenzo Nibid, Luca Frasca, Giovanna Sabarese, Daniela Righi, Silvia Taccogna, Pierfilippo Crucitti, Paolo Graziano, Giuseppe Perrone
Pathologica, 2022
Uncommon EGFR mutations in non-small-cell lung cancer
Marco Russano, Giuseppe Perrone, Giuseppina Rita Di Fazio, Alessandro Galletti, Fabrizio Citarella, Valentina Santo, Leonardo Brunetti, Alessia Vendittelli, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Precision Cancer Medicine, 2022
Prognostic role of hERG1 Potassium Channels in Neuroendocrine Tumours of the Ileum and Pancreas
Jessica Iorio, Lorenzo Antonuzzo, Emanuela Scarpi, Massimo D’Amico, Claudia Duranti, Luca Messerini, Clotilde Sparano, Damiano Caputo, Daniele Lavacchi, Domenico Borzomati, Alice Antonelli, Lorenzo Nibid, Giuseppe Perrone, Alessandro Coppola, Roberto Coppola, Francesco di Costanzo, Elena Lastraioli, Annarosa Arcangeli
International Journal of Molecular Sciences, 2022
Genome-Wide Identification and Validation of Gene Expression Biomarkers in the Diagnosis of Ovarian Serous Cystadenocarcinoma
Francesca Zalfa, Maria Grazia Perrone, Savina Ferorelli, Luna Laera, Ciro Leonardo Pierri, Anna Tolomeo, Vincenzo Dimiccoli, Giuseppe Perrone, Anna De Grassi, Antonio Scilimati
Cancers, 2022
Ineffective target therapy in non-small cell lung cancer harboring BRAF G466R mutation: a case report and biological rationale
Fabrizio Citarella, Marco Russano, Giuseppe Perrone, Giuseppina-Rita Di Fazio, Raffaele Giusti, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Precision Cancer Medicine, 2022
Role and evaluation of pathologic response in early breast cancer specimens after neoadjuvant therapy: consensus statement
Elena Guerini-Rocco, Gerardo Botti, Maria Pia Foschini, Caterina Marchiò, Mauro Giuseppe Mastropasqua, Giuseppe Perrone, Elena Roz, Alfredo Santinelli, Isabella Sassi, Viviana Galimberti, Luca Gianni, Giuseppe Viale
Tumori, 2022
Large−Scale Profiling of Extracellular Vesicles Identified miR−625−5p as a Novel Biomarker of Immunotherapy Response in Advanced Non−Small−Cell Lung Cancer Patients
Francesco Pantano, Francesca Zalfa, Michele Iuliani, Sonia Simonetti, Paolo Manca, Andrea Napolitano, Simone Tiberi, Marco Russano, Fabrizio Citarella, Simone Foderaro, Elisabetta Vulpis, Alessandra Zingoni, Laura Masuelli, Roberto Bei, Giulia Ribelli, Marzia Del Re, Romano Danesi, Bruno Vincenzi, Giuseppe Perrone, Giuseppe Tonini, Daniele Santini
Cancers, 2022
Preoperative Ultrasound-guided Sub-areolar Biopsy in Predicting Occult Nipple Involvement in Breast Cancer Patients: Proposal for a Methodological Approach
VITTORIO ALTOMARE, PAOLO ORSARIA, ANTONELLA GRASSO, LORENZA CAGGIATI, EDY IPPOLITO, FRANCESCO PANTANO, MATTEO SAMMARRA, CARLO ALTOMARE, GIUSEPPE PERRONE, GABRIELLA GULLOTTA, RITA CARINO
In Vivo, 2022
Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery
Federica Tavaglione, Antonio De Vincentis, Vincenzo Bruni, Ida Francesca Gallo, Simone Carotti, Dario Tuccinardi, Giuseppe Spagnolo, Ester Ciociola, Rosellina Margherita Mancina, Oveis Jamialahmadi, Rossella D’Alessio, Bruna Bottazzi, Silvia Manfrini, Antonio Picardi, Giuseppe Perrone, Paolo Pozzilli, Marco Caricato, Umberto Vespasiani‐Gentilucci, Stefano Romeo
Liver International, 2022
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study
Pasquale Pisapia, Francesco Pepe, Anna Baggi, Massimo Barberis, Antonio Galvano, Valerio Gristina, Fabrizio Mastrilli, Silvia Novello, Fabio Pagni, Silvia Pasini, Giuseppe Perrone, Daniela Righi, Antonio Russo, Giancarlo Troncone, Umberto Malapelle
Critical Reviews in Oncology Hematology, 2022
Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study
Bruna Cerbelli, Ilaria Girolami, Albino Eccher, Leopoldo Costarelli, Silvia Taccogna, Renzo Scialpi, Maria Benevolo, Teresa Lucante, Piero Luigi Alò, Francesca Stella, Maria Gemma Pignataro, Guido Fadda, Giuseppe Perrone, Giulia D’Amati, Maurizio Martini
Histopathology, 2022
The role of estrogen and progesterone receptors in the rotator cuff disease: a retrospective cohort study
Umile Giuseppe Longo, Alessandro Mazzola, Simone Carotti, Maria Francesconi, Simone Catapano, Francesco Magrì, Giuseppe Perrone, Sergio Morini, Sergio De Salvatore, Vincenzo Denaro
BMC Musculoskeletal Disorders, 2021
Molecular and histological traits of reduced lysosomal acid lipase activity in the fatty liver
Simone Carotti, Daniele Lettieri-Barbato, Fiorella Piemonte, Sergio Ruggiero, Marco Rosina, Francesca Zalfa, Maria Zingariello, Francesca Arciprete, Francesco Valentini, Maria Francesconi, Jessica D’Amico, Antonio De Vincentis, Andrea Baiocchini, Giuseppe Perrone, Raffaele Antonelli-Incalzi, Sergio Morini, Antonio Picardi, Katia Aquilano, Umberto Vespasiani-Gentilucci
Cell Death and Disease, 2021
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Npj Breast Cancer, 2021
Neonatal nav1.5 protein expression in human colorectal cancer: Immunohistochemical characterization and clinical evaluation
Elena Lastraioli, Scott P. Fraser, R. Mine Guzel, Jessica Iorio, Lapo Bencini, Emanuela Scarpi, Luca Messerini, Vincenzo Villanacci, Giulia Cerino, Niccolo’ Ghezzi, Giuseppe Perrone, Mustafa B. A. Djamgoz, Annarosa Arcangeli
Cancers, 2021
Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge
Simone Carotti, Maria Zingariello, Maria Francesconi, Laura D’Andrea, M. Ujue Latasa, Leticia Colyn, Maite G. Fernandez-Barrena, Rocco Simone Flammia, Mario Falchi, Daniela Righi, Giorgia Pedini, Francesco Pantano, Claudia Bagni, Giuseppe Perrone, Rosa Alba Rana, Matias A. Avila, Sergio Morini, Francesca Zalfa
Oncogene, 2021
Response to: Successful afatinib rechallenge in a patient with non-small cell lung cancer harboring EGFR G719C and S768I mutations
Fabrizio Citarella, Marco Russano, Giuseppe Perrone, Bruno Vincenzi, Giuseppe Tonini, Daniele Santini
Thoracic Cancer, 2021
Exploring deep pathomics in lung cancer
Charles Z. Liu, Rosa Sicilia, Matteo Tortora, Ermanno Cordelli, Lorenzo Nibid, Giovanna Sabarese, Giuseppe Perrone, Michele Fiore, Sara Ramella, Paolo Soda
Proceedings IEEE Symposium on Computer Based Medical Systems, 2021
Clinical outcomes among major breast cancer subtypes after neoadjuvant chemotherapy: Impact on breast cancer recurrence and survival
PAOLO ORSARIA, ANTONELLA GRASSO, EDY IPPOLITO, FRANCESCO PANTANO, MATTEO SAMMARRA, CARLO ALTOMARE, BARBARA CAGLI, FABIO COSTA, GIUSEPPE PERRONE, GEORGETA SOPONARU, LORENZA CAGGIATI, GIANLUCA VANNI, ORESTE CLAUDIO BUONOMO, VITTORIO ALTOMARE
Anticancer Research, 2021
The role of pathological method and clearance definition for the evaluation of margin status after pancreatoduodenectomy for periampullary cancer. Results of a multicenter prospective randomized trial
Gennaro Nappo, Domenico Borzomati, Alessandro Zerbi, Paola Spaggiari, Ugo Boggi, Daniela Campani, Sławomir Mrowiec, Łukasz Liszka, Alessandro Coppola, Michela Amato, Tommasangelo Petitti, Fabio Vistoli, Marco Montorsi, Giuseppe Perrone, Roberto Coppola, Damiano Caputo
Cancers, 2021
Impaired colonic contractility and intestinal permeability in symptomatic uncomplicated diverticular disease
Annamaria Altomare, Manuele Gori, Silvia Cocca, Simone Carotti, Maria Francesconi, Mentore Ribolsi, Sara Emerenziani, Giuseppe Perrone, Sergio Morini, Michele Cicala, Michele P L Guarino
Journal of Neurogastroenterology and Motility, 2021
Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab
Annamaria Ruzzo, Francesco Graziano, Irene Bagaloni, Maria Di Bartolomeo, Michele Prisciandaro, Giuseppe Aprile, Elena Ongaro, Bruno Vincenzi, Giuseppe Perrone, Daniele Santini, Lorenzo Fornaro, Caterina Vivaldi, Gianluca Tomasello, Fotios Loupakis, Sara Lonardi, Matteo Fassan, Michele Valmasoni, Donatella Sarti, Paola Lorenzini, Vincenzo Catalano, Renato Bisonni, Michela Del Prete, Guido Collina, Mauro Magnani
Gastric Cancer, 2020
Current prognostic and predictive biomarkers for gastrointestinal tumors in clinical practice
Matteo Fassan, Aldo Scarpa, Andrea Remo, Giovanna De Maglio, Giancarlo Troncone, Antonio Marchetti, Claudio Doglioni, Giuseppe Ingravallo, Giuseppe Perrone, Paola Parente, Claudio Luchini, Luca Mastracci
Pathologica, 2020
Tp53 mutation analysis in gastric cancer and clinical outcomes of patients with metastatic disease treated with ramucirumab/paclitaxel or standard chemotherapy
Francesco Graziano, Nicholas W. Fischer, Irene Bagaloni, Maria Di Bartolomeo, Sara Lonardi, Bruno Vincenzi, Giuseppe Perrone, Lorenzo Fornaro, Elena Ongaro, Giuseppe Aprile, Renato Bisonni, Michele Prisciandaro, David Malkin, Jean Gariépy, Matteo Fassan, Fotios Loupakis, Donatella Sarti, Michela Del Prete, Vincenzo Catalano, Paolo Alessandroni, Mauro Magnani, Annamaria Ruzzo
Cancers, 2020
Lipophagy Impairment Is Associated With Disease Progression in NAFLD
Simone Carotti, Katia Aquilano, Francesca Zalfa, Sergio Ruggiero, Francesco Valentini, Maria Zingariello, Maria Francesconi, Giuseppe Perrone, Francesca Alletto, Raffaele Antonelli-Incalzi, Antonio Picardi, Sergio Morini, Daniele Lettieri-Barbato, Umberto Vespasiani-Gentilucci
Frontiers in Physiology, 2020
Heterogeneous risk profiles among B3 breast lesions of uncertain malignant potential
Paolo Orsaria, Antonella Grasso, Rita Carino, Emanuele Caredda, Matteo Sammarra, Carlo Altomare, Carla Rabitti, Gabriella Gullotta, Giuseppe Perrone, Francesco Pantano, Oreste Claudio Buonomo, Vittorio Altomare
Tumori, 2020
hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients
Jessica Iorio, Elena Lastraioli, Lorenzo Tofani, Giulia Petroni, Lorenzo Antonuzzo, Luca Messerini, Giuseppe Perrone, Damiano Caputo, Maria Francesconi, Maria Michelina Amato, Moris Cadei, Giuseppina Arcangeli, Vincenzo Villanacci, Luca Boni, Roberto Coppola, Francesco Di Costanzo, Annarosa Arcangeli
Translational Oncology, 2020
Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma
Michele Fiore, Pasquale Trecca, Giuseppe Perrone, Michelina Amato, Daniela Righi, Lucio Trodella, Rolando M. D’Angelillo, Sara Ramella
Tumori, 2019
A close relationship between HIF-1α expression and bone metastases in advanced NSCLC, a retrospective analysis
Oncotarget, 2019
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Tomás Pascual, Miguel Martin, Aranzazu Fernández-Martínez, Laia Paré, Emilio Alba, Álvaro Rodríguez-Lescure, Giuseppe Perrone, Javier Cortés, Serafín Morales, Ana Lluch, Ander Urruticoechea, Blanca González-Farré, Patricia Galván, Pedro Jares, Adela Rodriguez, Nuria Chic, Daniela Righi, Juan Miguel Cejalvo, Giuseppe Tonini, Barbara Adamo, Maria Vidal, Patricia Villagrasa, Montserrat Muñoz, Aleix Prat
Frontiers in Oncology, 2019
Impairment of GH/IGF-1 Axis in the Liver of Patients with HCV-Related Chronic Hepatitis
Simone Carotti, Michele Guarino, Francesco Valentini, Silvio Porzio, Umberto Vespasiani-Gentilucci, Giuseppe Perrone, Maria Zingariello, Paolo Gallo, Michele Cicala, Antonio Picardi, Sergio Morini
Hormone and Metabolic Research, 2018
Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale
Andrea Casadei Gardini, Luca Faloppi, Serena De Matteis, Francesco Giuseppe Foschi, Nicola Silvestris, Francesco Tovoli, Vincenzo Palmieri, Giorgia Marisi, Oronzo Brunetti, Umberto Vespasiani-Gentilucci, Giuseppe Perrone, Martina Valgiusti, Anna Maria Granato, Giorgio Ercolani, Giulia Negrini, Emiliano Tamburini, Giuseppe Aprile, Alessandro Passardi, Daniele Santini, Stefano Cascinu, Giovanni Luca Frassineti, Mario Scartozzi
European Journal of Cancer, 2017
The fragile X mental retardation protein regulates tumor invasiveness-related pathways in melanoma cells
Francesca Zalfa, Vincenzo Panasiti, Simone Carotti, Maria Zingariello, Giuseppe Perrone, Laura Sancillo, Laura Pacini, Flavie Luciani, Vincenzo Roberti, Silvia D'Amico, Rosa Coppola, Simona Osella Abate, Rosa Alba Rana, Anastasia De Luca, Mark Fiers, Valentina Melocchi, Fabrizio Bianchi, Maria Giulia Farace, Tilmann Achsel, Jean-Christophe Marine, Sergio Morini, Claudia Bagni
Cell Death and Disease, 2017
Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma
Bruno Vincenzi, Silvia Stacchiotti, Paola Collini, Francesco Pantano, Carla Rabitti, Giuseppe Perrone, Michele Iuliani, Alfonso Baldi, Giuseppe Badalamenti, Roberta Sanfilippo, Daniele Santini, Andrea Onetti Muda, Alessandro Gronchi, Paolo Casali, Angelo Paolo Dei Tos, Giuseppe Tonini
British Journal of Cancer, 2017
Reelin expression in human liver of patients with chronic hepatitis C infection
Simone Carotti, Giuseppe Perrone, Michelina Amato, Umberto Vespasiani Gentilucci, Daniela Righi, Maria Francesconi, Claudio Pellegrini, Francesca Zalfa, Maria Zingariello, Antonio Picardi, Andrea Onetti Muda, Sergio Morini
European Journal of Histochemistry, 2017
HER2 Status in Gastric Cancer: Comparison between Primary and Distant Metastatic Disease
Michelina Amato, Giuseppe Perrone, Daniela Righi, Claudio Pellegrini, Carla Rabitti, Francesco Di Matteo, Pierfilippo Crucitti, Damiano Caputo, Roberto Coppola, Giuseppe Tonini, Daniele Santini, Andrea Onetti Muda
Pathology and Oncology Research, 2017
Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2- negative breast cancer
Aranzazu Fernandez-Martinez, Tomás Pascual, Giuseppe Perrone, Serafin Morales, Juan de la Haba, Milagros González-Rivera, Patricia Galván, Francesca Zalfa, Michela Amato, Lucia Gonzalez, Miquel Prats, Federico Rojo, Luis Manso, Laia Paré, Immaculada Alonso, Joan Albanell, Ana Vivancos, Antonio González, Judit Matito, Sonia González, Pedro Fernandez, Barbara Adamo, Montserrat Muñoz, Margarita Viladot, Carme Font, Francisco Aya, Maria Vidal, Rosalía Caballero, Eva Carrasco, Vittorio Altomare, Giuseppe Tonini, Aleix Prat, Miguel Martin
Oncotarget, 2017
Surgical margins for duodenopancreatectomy
R. Coppola, M. Cartillone, D. Borzomati, G. Nappo, S. Valeri, T. Petitti, G. Perrone
Updates in Surgery, 2016
Microscopic residual tumor after pancreaticoduodenectomy: Is standardization of pathological examination worthwhile?
Domenico Borzomati, Giuseppe Perrone, Gennaro Nappo, Sergio Valeri, Michela Amato, Tommasangelo Petitti, Andrea Onetti Muda, Roberto Coppola
Pancreas, 2016
Portal inflammation during NAFLD is frequent and associated with the early phases of putative hepatic progenitor cell activation
Simone Carotti, Umberto Vespasiani-Gentilucci, Giuseppe Perrone, Antonio Picardi, Sergio Morini
Journal of Clinical Pathology, 2015
Incidence and prognostic impact of para-aortic lymph nodes metastases during pancreaticoduodenectomy for peri-ampullary cancer
Gennaro Nappo, Domenico Borzomati, Giuseppe Perrone, Sergio Valeri, Michela Amato, Tommasangelo Petitti, Roberto Coppola
HPB, 2015
Heterogeneity of KRAS, NRAS, BRAF and PIK3CA mutations in metastatic colorectal cancer and potential effects on therapy in the CAPRI GOIM trial
N. Normanno, A.M. Rachiglio, M. Lambiase, E. Martinelli, F. Fenizia, C. Esposito, C. Roma, T. Troiani, D. Rizzi, F. Tatangelo, G. Botti, E. Maiello, G. Colucci, F. Ciardiello, F. Giuliani, G. Simone, A. Febbraro, E. Tommaselli, S. Cinieri, M. Criscuolo, A. Perrino, A. Rinaldi, R. Bordonaro, M. Manusia, S. Romito, P. Bufo, G. Cartenì, M. Biglietto, O. Nappi, A. Cardarelli, E. Montesarchio, P. Micheli, G. Nasti, N. Chicchinelli, A. Iannaccone, A. Russo, D. Cabibi, P. Giaccone, C. Barone, G. Rindi, G. Tonini, A. Onetti Muda, G. Perrone, T. Latiano, P. Graziano, S. Pisconti, A. Sebastio
Annals of Oncology, 2015
HERG1 channels drive tumour malignancy and may serve as prognostic factor in pancreatic ductal adenocarcinoma
E Lastraioli, G Perrone, A Sette, A Fiore, O Crociani, S Manoli, M D'Amico, M Masselli, J Iorio, M Callea, D Borzomati, G Nappo, F Bartolozzi, D Santini, L Bencini, M Farsi, L Boni, F Di Costanzo, A Schwab, A Onetti Muda, R Coppola, A Arcangeli
British Journal of Cancer, 2015
Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD
Umberto Vespasiani‐Gentilucci, Simone Carotti, Giuseppe Perrone, Chiara Mazzarelli, Giovanni Galati, Andrea Onetti‐Muda, Antonio Picardi, Sergio Morini
Liver International, 2015
Deregulation of dicer and mir-155 expression in liposarcoma
Bruno Vincenzi, Michele Iuliani, Alice Zoccoli, Francesco Pantano, Marco Fioramonti, Delia De Lisi, Anna Maria Frezza, Carla Rabitti, Giuseppe Perrone, Andrea Onetti Muda, Antonio Russo, Antonio Giordano, Daniele Santini, Angelo Paolo Dei Tos, Giuseppe Tonini
Oncotarget, 2015
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
Bruno Vincenzi, Chiara Cremolini, Andrea Sartore-Bianchi, Antonio Russo, Francesco Mannavola, Giuseppe Perrone, Francesco Pantano, Fotios Loupakis, Daniele Rossini, Elena Ongaro, Erica Bonazzina, Emanuela Dell’Aquila, Marco Imperatori, Alice Zoccoli, Giuseppe Bronte, Giovanna De Maglio, Gabriella Fontanini, Clara Natoli, Alfredo Falcone, Daniele Santini, Andrea Onetti-Muda, Salvatore Siena, Giuseppe Tonini, Giuseppe Aprile
Oncotarget, 2015
Complete pathological response after FOLFIRINOX for locally advanced pancreatic cancer. the beginning of a new era? Case report and review of the literature
S. Valeri, D. Borzomati, G. Nappo, G. Perrone, D. Santini, R. Coppola
Pancreatology, 2014
Evaluation of microRNA-10b prognostic significance in a prospective cohort of breast cancer patients
Paola Parrella, Raffaela Barbano, Barbara Pasculli, Andrea Fontana, Massimiliano Copetti, Vanna Valori, Maria Poeta, Giuseppe Perrone, Daniela Righi, Marina Castelvetere, Michelina Coco, Teresa Balsamo, Maria Morritti, Fabio Pellegrini, Andrea Onetti-Muda, Evaristo Maiello, Roberto Murgo, Vito Fazio
Molecular Cancer, 2014
Reply to 'hospital volume, margin status, and long-term survival after pancreaticoduodenectomy for pancreatic adenocarcinoma' (Am Surg 2012;78:225-9)
Domenico Borzomati, Gennaro Nappo, Giuseppe Perrone, Roberto Coppola
American Surgeon, 2014
Malignant transformation of well-differentiated papillary mesothelioma 13 years after the diagnosis: A case report
Luisa Costanzo, Simone Scarlata, Giuseppe Perrone, Luigi Rossi, Anselmo Papa, Francesco Maria Di Matteo, Giuseppe Tonini, Andrea Onetti Muda, Raffaele Antonelli‐Incalzi, Silverio Tomao
Clinical Respiratory Journal, 2014
Toll-like receptor-4 is involved in hepatic fibrogenesis in the course of non-alcoholic fatty liver disease
Italian Journal of Anatomy and Embryology, 2013
Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer
Francesca Suriano, Daniele Santini, Giuseppe Perrone, Michela Amato, Bruno Vincenzi, Giuseppe Tonini, Andrea Onetti Muda, Sara Boggia, Maurizio Buscarini, Francesco Pantano
Journal of Experimental and Clinical Cancer Research, 2013
US-guided application of Nd:YAG laser in porcine pancreatic tissue: An ex vivo study and numerical simulation
Francesco Di Matteo, Margareth Martino, Roberta Rea, Monica Pandolfi, Francesco Panzera, Egidio Stigliano, Emiliano Schena, Paola Saccomandi, Sergio Silvestri, Claudio Maurizio Pacella, Luca Breschi, Giuseppe Perrone, Roberto Coppola, Guido Costamagna
Gastrointestinal Endoscopy, 2013
The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients
Francesco Pantano, Pierpaolo Berti, Francesco Maria Guida, Giuseppe Perrone, Bruno Vincenzi, Michelina Maria Carla Amato, Daniela Righi, Emanuela Dell'Aquila, Francesco Graziano, Vincenzo Catalano, Marco Caricato, Sergio Rizzo, Andrea Onetti Muda, Antonio Russo, Giuseppe Tonini, Daniele Santini
Journal of Cellular and Molecular Medicine, 2013
Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients
Bruno Vincenzi, Alice Zoccoli, Gaia Schiavon, Michele Iuliani, Francesco Pantano, Emanuela Dell’Aquila, Raffaele Ratta, Andrea Onetti Muda, Giuseppe Perrone, Chiara Brunelli, Pierpaolo Correale, Elisabetta Riva, Antonio Russo, Fotios Loupakis, Alfredo Falcone, Daniele Santini, Giuseppe Tonini
European Journal of Cancer, 2013
Carcinoma of the ampulla of vater: Morphological and immunophenotypical classification predicts overall survival
Sergio Morini, Giuseppe Perrone, Domenico Borzomati, Bruno Vincenzi, Carla Rabitti, Daniela Righi, Federica Castri, Andrea D. Manazza, Daniele Santini, Giuseppe Tonini, Roberto Coppola, Andrea Onetti Muda
Pancreas, 2013
Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors
Maria Luana Poeta, Emanuela Massi, Paola Parrella, Pasquale Pellegrini, Mariangela De Robertis, Massimiliano Copetti, Carla Rabitti, Giuseppe Perrone, Andrea Onetti Muda, Francesca Molinari, Elena Zanellato, Stefano Crippa, Damiano Caputo, Marco Caricato, Milo Frattini, Roberto Coppola, Vito Michele Fazio
Genes Chromosomes and Cancer, 2012
In Situ Identification of CD44+/CD24- Cancer Cells in Primary Human Breast Carcinomas
Giuseppe Perrone, Laura Maria Gaeta, Mariagiovanna Zagami, Francesca Nasorri, Roberto Coppola, Domenico Borzomati, Francesco Bartolozzi, Vittorio Altomare, Lucio Trodella, Giuseppe Tonini, Daniele Santini, Andrea Cavani, Andrea Onetti Muda
Plos One, 2012
High let-7a microRNA levels in KRAS-mutated colorectal carcinomas may rescue anti-EGFR therapy effects in patients with chemotherapy-refractory metastatic disease
Annamaria Ruzzo, Francesco Graziano, Bruno Vincenzi, Emanuele Canestrari, Giuseppe Perrone, Nadia Galluccio, Vincenzo Catalano, Fotios Loupakis, Carla Rabitti, Daniele Santini, Giuseppe Tonini, Giammaria Fiorentini, David Rossi, Alfredo Falcone, Mauro Magnani
Oncologist, 2012
HER2 amplification status in gastric and gastro-oesophageal junction cancer in routine clinical practice: Which sample should be used?
Giuseppe Perrone, Michelina Amato, Marcella Callea, Carla Rabitti, Daniela Righi, Pierfilippo Crucitti, Roberto Coppola, Andrea Onetti Muda
Histopathology, 2012
PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients
Bruno Vincenzi, Daniele Santini, Giuseppe Perrone, Francesco Graziano, Fotios Loupakis, Gaia Schiavon, Anna Maria Frezza, Anna Maria Ruzzo, Sergio Rizzo, Pierfilippo Crucitti, Sara Galluzzo, Alice Zoccoli, Carla Rabitti, Andrea Onetti Muda, Antonio Russo, Alfredo Falcone, Giuseppe Tonini
Journal of Cellular Physiology, 2012
Toll-like receptor-4 expression by hepatic progenitor cells and biliary epithelial cells in HCV-related chronic liver disease
Umberto Vespasiani-Gentilucci, Simone Carotti, Andrea Onetti-Muda, Giuseppe Perrone, Stefano Ginanni-Corradini, Maria U Latasa, Matias A Avila, Guido Carpino, Antonio Picardi, Sergio Morini
Modern Pathology, 2012
High RAD51 mRNA expression characterize estrogen receptor-positive/ progesteron receptor-negative breast cancer and is associated with patient's outcome
Raffaela Barbano, Massimiliano Copetti, Giuseppe Perrone, Valerio Pazienza, Lucia Anna Muscarella, Teresa Balsamo, Clelia Tiziana Storlazzi, Maria Ripoli, Monica Rinaldi, Vanna Maria Valori, Tiziana Pia Latiano, Evaristo Maiello, Pietro Stanziale, Massimo Carella, Alessandra Mangia, Fabio Pellegrini, Michele Bisceglia, Andrea Onetti Muda, Vittorio Altomare, Roberto Murgo, Vito Michele Fazio, Paola Parrella
International Journal of Cancer, 2011
Receptor activator of NF-kB (rank) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients
Daniele Santini, Gaia Schiavon, Bruno Vincenzi, Laura Gaeta, Francesco Pantano, Antonio Russo, Cinzia Ortega, Camillo Porta, Sara Galluzzo, Grazia Armento, Nicla La Verde, Cinzia Caroti, Isabelle Treilleux, Alessandro Ruggiero, Giuseppe Perrone, Raffaele Addeo, Philippe Clezardin, Andrea Onetti Muda, Giuseppe Tonini
Plos One, 2011
Subcutaneous Ewing sarcoma/PNET as a second cancer in a previously irradiated young patient. An uncommon type of post-irradiation soft tissue sarcoma
Pathologica, 2011
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases
Daniele Santini, Giuseppe Perrone, Ilaria Roato, Laura Godio, Francesco Pantano, Donatella Grasso, Antonio Russo, Bruno Vincenzi, Maria Elisabetta Fratto, Roberto Sabbatini, Chiara Della Pepa, Camillo Porta, Alessandro Del Conte, Gaia Schiavon, Alfredo Berruti, Rosa Maria Tomasino, Mauro Papotti, Nicola Papapietro, Andrea Onetti Muda, Vincenzo Denaro, Giuseppe Tonini
Journal of Cellular Physiology, 2011
Non-cirrhotic portal hypertension with large regenerative nodules: A diagnostic challenge
Umberto Vespasiani Gentilucci
World Journal of Gastroenterology, 2011
Recurrent scrotal hemangiomas during treatment with sunitinib
Giuseppe Tonini, Salvatore Intagliata, Barbara Cagli, Francesco Segreto, Giuseppe Perrone, Andrea Onetti Muda, Daniele Santini, Paolo Persichetti
Journal of Clinical Oncology, 2010
PML down-regulation in soft tissue sarcomas
Bruno Vincenzi, Giuseppe Perrone, Daniele Santini, Federica Grosso, Marianna Silletta, Annamaria Frezza, Sabrina Rossi, Antonio Russo, Carla Rabitti, Nicola Gebbia, Giuseppe Badalamenti, Paolo Casali, Andrea Onetti Muda, Angelo Paolo dei Tos, Giuseppe Tonini
Journal of Cellular Physiology, 2010
Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients
S. Carotti, M. P. L. Guarino, M. Cicala, G. Perrone, R. Alloni, F. Segreto, C. Rabitti, S. Morini
Neurogastroenterology and Motility, 2010
Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer
Daniele Santini, Bruno Vincenzi, Maria Elisabetta Fratto, Giuseppe Perrone, Raymond Lai, Vincenzo Catalano, Carol Cass, Pier Adelchi Ruffini, Chiara Spoto, Pietro Muretto, Sergio Rizzo, Andrea Onetti Muda, John R. Mackey, Antonio Russo, Giuseppe Tonini, Francesco Graziano
Journal of Cellular Physiology, 2010
Predictors of benefit in colorectal cancer treated with cetuximab: Are we getting "lost in translationAL"?
Chiara Cremolini, Fotios Loupakis, Annamaria Ruzzo, Giuseppe Perrone, Eliana Rulli, Bruno Vincenzi, Giuseppe Tonini, Francesco Graziano, Andrea Onetti Muda, Alfredo Falcone
Journal of Clinical Oncology, 2010
Urinary complications from breast cancer metastasis: case report and review of the literature.
Il Giornale Di Chirurgia, 2010
Human equilibrative nucleosidetransporter 1 and carcinoma of the ampulla of vater: Expression differences in tumour histotypes
G. Perrone, S. Morini, D. Santini, C. Rabitti, B. Vincenzi, R. Alloni, A. Antinori, P. Magistrelli, R. Lai, C. Cass, J. R. Mackey, R. Coppola, G. Tonini, A. Onetti Muda
European Journal of Histochemistry, 2010
Promyelocytic leukemia (PML) gene expression is a prognostic factor in ampullary cancer patients
B. Vincenzi, D. Santini, G. Perrone, A. Russo, V. Adamo, S. Rizzo, F. Castri, A. Antinori, R. Alloni, P.F. Crucitti, S. Morini, C. Rabitti, F.M. Vecchio, P. Magistrelli, R. Coppola, G. Tonini
Annals of Oncology, 2009
Intercellular space diameters of the oesophageal epithelium in NERD patients: Head to head comparison between light and electron microscopy analysis
M. Ribolsi, G. Perrone, R. Caviglia, M. Gentile, S. Emerenziani, M.P. Luca Guarino, T. Petitti, M. Cicala
Digestive and Liver Disease, 2009
Caveolin-1 expression in human breast lobular cancer progression
Giuseppe Perrone, Vittorio Altomare, Mariagiovanna Zagami, Sergio Morini, Tommaso Petitti, Cleonice Battista, Andrea Onetti Muda, Carla Rabitti
Modern Pathology, 2009
Breast-like vulvar lesion with concurrent breast cancer: A case report and critical literature review
In Vivo, 2009
Solitary fibrous tumour of thyroid: Report of two cases with immunohistochemical features and literature review
Giuseppe Santeusanio, Stefania Schiaroli, Angela Ortenzi, Antonino Mulè, Giuseppe Perrone, Guido Fadda
Head and Neck Pathology, 2008
Decreased number of activated macrophages in gallbladder muscle layer of cholesterol gallstone patients following ursodeoxycholic acid
M P L Guarino, S Carotti, S Morini, G Perrone, J Behar, A Altomare, R Alloni, R Caviglia, S Emerenziani, C Rabitti, M Cicala
Gut, 2008
High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice
Daniele Santini, Fotios Loupakis, Bruno Vincenzi, Irene Floriani, Irene Stasi, Emanuele Canestrari, Eliana Rulli, Paolo Enrico Maltese, Francesca Andreoni, Gianluca Masi, Francesco Graziano, Giacomo Giulio Baldi, Lisa Salvatore, Antonio Russo, Giuseppe Perrone, Maria Rosa Tommasino, Mauro Magnani, Alfredo Falcone, Giuseppe Tonini, Annamaria Ruzzo
Oncologist, 2008
Intratumoural FOXP3-positive regulatory T cells are associated with adverse prognosis in radically resected gastric cancer
Giuseppe Perrone, Pier Adelchi Ruffini, Vincenzo Catalano, Cathie Spino, Daniele Santini, Pietro Muretto, Chiara Spoto, Costantino Zingaretti, Valerio Sisti, Paolo Alessandroni, Paolo Giordani, Andrea Cicetti, Silvia D’Emidio, Sergio Morini, Annamaria Ruzzo, Mauro Magnani, Giuseppe Tonini, Carla Rabitti, Francesco Graziano
European Journal of Cancer, 2008
Dynamic contrast enhanced magnetic resonance imaging of the terminal ileum: Differentiation of activity of Crohn's disease
Riccardo Del Vescovo, Ilaria Sansoni, Renato Caviglia, Mentore Ribolsi, Giuseppe Perrone, Emanuele Leoncini, Rosario Francesco Grasso, Michele Cicala, Bruno Beomonte Zobel
Abdominal Imaging, 2008
Human equilibrative nucleoside transporter 1 (hENT1) protein is associated with short survival in resected ampullary cancer
D. Santini, G. Perrone, B. Vincenzi, R. Lai, C. Cass, R. Alloni, C. Rabitti, A. Antinori, F. Vecchio, S. Morini, P. Magistrelli, R. Coppola, J.R. Mackey, G. Tonini
Annals of Oncology, 2008
COX-2 localization within plasma membrane caveolae-like structures in human lobular intraepithelial neoplasia of the breast
Giuseppe Perrone, Mariagiovanna Zagami, Vittorio Altomare, Cleonice Battista, Sergio Morini, Carla Rabitti
Virchows Archiv, 2007
ApoE gene delivery inhibits severe hypercholesterolemia in newborn ApoE-KO mice
Emanuela Signori, Monica Rinaldi, Daniela Fioretti, Sandra Iurescia, Davide Seripa, Giuseppe Perrone, Giuseppe Danilo Norata, Alberico Luigi Catapano, Vito Michele Fazio
Biochemical and Biophysical Research Communications, 2007
COX-2 expression in lobular in situneoplasia of the breast: Correlation with histopathological grading system according to the Tavassoli classification
G Perrone, M Zagami, D Santini, B Vincenzi, G Gullotta, S Morini, C Battista, G Guerriero, V Altomare, G Tonini, C Rabitti
Histopathology, 2007
Alternative BCR/ABL Splice Variants in Philadelphia Chromosome-Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches
Gisella Volpe, Alessandro Cignetti, Cristina Panuzzo, Mirela Kuka, Katiuscia Vitaggio, Mara Brancaccio, Giuseppe Perrone, Monica Rinaldi, Giuseppina Prato, Milena Fava, Massimo Geuna, Marisa Pautasso, Claudia Casnici, Emanuela Signori, Giancarlo Tonon, Guido Tarone, Ornella Marelli, Vito M. Fazio, Giuseppe Saglio
Cancer Research, 2007
Vocal cord metastasis from breast cancer
Rosario Francesco Grasso, Carlo Cosimo Quattrocchi, Sara Piciucchi, Giuseppe Perrone, Fabrizio Salvinelli, Carla Rabitti, Bruno Beomonte Zobel
Journal of Clinical Oncology, 2007
Immunohistochemistry and differential diagnosis of a solitary flat laryngeal xanthoma: A case report
In Vivo, 2007
Collagen changes in the ureteropelvic junction after failed antegrade endopyelotomy
Federico Sergi, Gerardo P. Flammia, Antonio Alcini, Giuseppe Perrone, Salvatore Guaglianone, Ester Forastiere, Carla Rabitti, Michele Gallucci
Journal of Endourology, 2007
Reelin expression in human prostate cancer: A marker of tumor aggressiveness based on correlation with grade
Giuseppe Perrone, Bruno Vincenzi, Mariagiovanna Zagami, Daniele Santini, Roger Panteri, Gerardo Flammia, Alfio Verzì, Daniela Lepanto, Sergio Morini, Antonio Russo, Vivian Bazan, Rosa M Tomasino, Vincenza Morello, Giuseppe Tonini, Carla Rabitti
Modern Pathology, 2007
Expression and heterodimer-binding activity of Ku70 and Ku80 in human non-melanoma skin cancer
P Parrella, P Mazzarelli, E Signori, G Perrone, G F Marangi, C Rabitti, M Delfino, M Prencipe, A P Gallo, M Rinaldi, G Fabbrocini, S Delfino, P Persichetti, V M Fazio
Journal of Clinical Pathology, 2006
COX-2 expression of ampullary carcinoma: Correlation with different histotypes and clinicopathological parameters
Giuseppe Perrone, Daniele Santini, Mariagiovanna Zagami, Bruno Vincenzi, Alfio Verzì, Sergio Morini, Domenico Borzomati, Roberto Coppola, Armando Antinori, Paolo Magistrelli, Giuseppe Tonini, Carla Rabitti
Virchows Archiv, 2006
Subcellular shift of the hepatic growth hormone receptor with progression of hepatitis C virus-related chronic liver disease
U Vespasiani Gentilucci, G Perrone, G Galati, D D'Avola, E M Zardi, C Rabitti, A Bianchi, E De Dominicis, A Afeltra, A Picardi
Histopathology, 2006
COX-2 expression in ampullary carcinoma: Correlation with angiogenesis process and clinicopathological variables
G Perrone, D Santini, A Verzì, B Vincenzi, D Borzomati, F Vecchio, R Coppola, A Antinori, P Magistrelli, G Tonini, C Rabitti
Journal of Clinical Pathology, 2006
Cell cycle alterations and lung cancer
Histology and Histopathology, 2006
An increase of CA 19.9 as the first clinical sign of ileocecal valve metastasis from breast cancer
In Vivo, 2006
DNA end binding activity and Ku70/80 heterodimer expression in human colorectal tumor
Paola Mazzarelli
World Journal of Gastroenterology, 2005
Pleomorphic adenoma of the breast
Enrico Dominicis, Giuseppe Perrone, Alfio Verzi, Antonella Bianchi, Vittorio Altomare, Bruno Beomonte Zobel, Carla Rabitti
Breast Journal, 2005
Vascular endothelial growth factor (VEGF) expression is not associated with prognosis in patients with radically resected ampullary carcinoma [3]
D. Santini, B. Vincenzi, G. Perrone, C. Rabitti, D. Borzomati, S. Valeri, R. Coppola, P. Magistrelli, G. Tonini
Annals of Oncology, 2005
Tumour proliferation, angiogenesis, and ploidy status in human colon cancer
E Cristi, G Perrone, G Toscano, A Verzì, S Nori, D Santini, G Tonini, A Vetrani, A Fabiano, C Rabitti
Journal of Clinical Pathology, 2005
Prognostic role of Thymidylate Synthase polymorphisms in gastric cancer patients treated with surgery and adjuvant chemotherapy
Kazuyuki Kawakami, Francesco Graziano, Go Watanabe, Annamaria Ruzzo, Daniele Santini, Vincenzo Catalano, Renato Bisonni, Federica Arduini, Italo Bearzi, Stefano Cascinu, Pietro Muretto, Giuseppe Perrone, Carla Rabitti, Lucio Giustini, Giuseppe Tonini, Francesca Pizzagalli, Mauro Magnani
Clinical Cancer Research, 2005
COX-2 expression in DCIS: Correlation with VEGF, HER-2/neu, prognostic molecular markers and clinicopathological features
G Perrone, D Santini, B Vincenzi, M Zagami, A La Cesa, A Bianchi, V Altomare, A Primavera, C Battista, A Vetrani, G Tonini, C Rabitti
Histopathology, 2005
A rare case of solitary fibrous tumour of the pre-sacral space: Morphological and immunohistochemical features
In Vivo, 2005
Thymidylate synthase expression in normal colonic mucosa: A predictive marker of toxicity in colorectal cancer patients receiving 5-fluorouracil-based adjuvant chemotherapy
Daniele Santini, Bruno Vincenzi, Giuseppe Perrone, Carla Rabitti, Domenico Borzomati, Marco Caricato, Annalisa La Cesa, Claudia Grilli, Alfio Verzì, Roberto Coppola, Giuseppe Tonini
Oncology, 2004
Correlation of p53 and bcl-2 expression with vascular endothelial growth factor (VEGF), microvessel density (MVD) and clinico-pathological features in colon cancer
G Perrone, B Vincenzi, D Santini, A Verzı̀, G Tonini, A Vetrani, C Rabitti
Cancer Letters, 2004
Differential modulation of Ku70/80 DNA-binding activity in a patient with multiple basal cell carcinomas
Paola Mazzarelli, Carla Rabitti, Paola Parrella, Davide Seripa, Paolo Persichetti, Giovanni Francesco Marangi, Giuseppe Perrone, Maria Luana Poeta, Mario Delfino, Vito Michele Fazio
Journal of Investigative Dermatology, 2003
Spindle cell non-pleomorphic atypical fibroxanthoma. Histological aspects and presentation of one case
Giornale Italiano Di Dermatologia E Venereologia, 2003
Revascularization and remodeling of transplanted pancreatic islets
C Rastellini, V Zuber, G Perrone, L Cicalese, E Gaudio, E Benedetti, S Morini
Transplantation Proceedings, 2001
Surgical treatment of portal hypertension: An experience to be forgotten?
Chirurgia, 1998
Surgical treatment of esophageal cancer
Chirurgia, 1994
Antiphospholipid antibody syndrome and venous thrombosis
Chirurgia, 1994
Early diagnosis of pancreatic carcinoma in a selected group of people
Chirurgia, 1994
Total parenteral nutrition in acute severe pancreatitis
Chirurgia, 1991
Treatment of common bile duct stones. Experience on 112 cases
Chirurgia, 1990
Apendectomy: A topical problem
Chirurgia, 1990
Biliary cystadenoma
Chirurgia, 1990
Peptic stenosis of the oesophagus: New therapeutic thinking
Chirurgia, 1990
Choledochoduodenal anastomoses in benign and malignant biliary diseases
Chirurgia, 1990
Palliative treatment of obstructive jaundice due to neoplastic disease
Chirurgia, 1989
Our experience in the treatment of obstructive jaundice by percutaneous transhepatic drainage
Chirurgia, 1988
Prophylaxis of surgical infections
Minerva Chirurgica, 1988
Warren's distal splenorenal anastomosis. Current status
Minerva Chirurgica, 1986
Hiatal hernia not complicated by esophageal stenosis. Physiopathology and treatment
Minerva Chirurgica, 1986
Effects of cimetidine on in vitro transformation of peripheral monocytes to macrophages in healthy volunteers and cancer patients
A. Giulivi, L. Cilano, L. Roncoroni, A. Petrella, G. Perrone, U. Visca, M.P. Spina, M. Ventura, F. Rossi, A. Massari, G. Santi
International Journal of Immunopharmacology, 1986
Morphological and structural classification of gallstones
Minerva Medica, 1985
Primary gastric lymphoma
Minerva Chirurgica, 1985
A case of extensive retroperitoneal haemangiopericytoma
Minerva Chirurgica, 1984
A case of glomus tumor of the stomach
Clinica Terapeutica, 1983

Giuseppe Perrone

RESEARCH, TEACHING, or OTHER INTERESTS

Scopus Publications

RECENT SCHOLAR PUBLICATIONS

MOST CITED SCHOLAR PUBLICATIONS